Who Paid My Doc
John Corl
Interventional Cardiology Cincinnati, OH Medical Doctor
NPI 1790778595 CMS profile 36593
7545 Beechmont Ave, Cincinnati, OH 45255
General payments
$389,690
Research payments
$0
Ownership & investment interest
$89,687
Research they led as principal investigator
$403,033
Through program year 2025, John Corl of Cincinnati, OH is reported in the CMS Open Payments database as having received $389,690 across 561 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $403,033 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $89,687 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $144,553 | 145 | |
| 2024 | General | $77,071 | 86 | |
| 2023 | General | $52,554 | 90 | |
| 2022 | General | $67,871 | 68 | |
| 2021 | General | $30,883 | 23 | |
| 2020 | General | $7,734 | 35 | |
| 2019 | General | $9,024 | 114 | |
| 2024 | Ownership | $89,687 | 1 |
Beside peers
- John Corl
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to John Corl were reported at $144,553. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | John Corl | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $9,024 | $1,097 | $329–$3,048 | $163 |
| 2020 | $7,734 | $473 | $161–$1,480 | $114 |
| 2021 | $30,883 | $677 | $233–$1,827 | $132 |
| 2022 | $67,871 | $978 | $333–$2,724 | $149 |
| 2023 | $52,554 | $1,136 | $382–$2,986 | $160 |
| 2024 | $77,071 | $1,181 | $395–$3,326 | $164 |
| 2025 | $144,553 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 29 drugsPart D claims
1,483
Drug cost
$197,930
Branded share of claims
22.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 115 | $122,690 | |
| Xarelto Rivaroxaban | Brand | 47 | $49,211 | |
| Repatha Sureclick Evolocumab | Brand | 12 | $12,354 | |
| Metoprolol Succinate | Generic | 164 | $1,877 | |
| Rosuvastatin Calcium | Generic | 105 | $1,818 | |
| Ranolazine Er Ranolazine | Brand | 23 | $1,305 | |
| Atorvastatin Calcium | Generic | 112 | $1,091 | |
| Carvedilol | Generic | 99 | $843 | |
| Amlodipine Besylate | Generic | 146 | $822 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 30 | $756 |
The 10 drugs with the highest cost, of 29 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 79 billing codesPaid by Medicare
$162,367
Medicare patients
659
Services billed
1,814
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 72% | |
| Arthritis | 53% | |
| Diabetes | 39% | |
| Heart failure | 36% | |
| Atrial fibrillation | 36% | |
| Chronic kidney disease | 33% | |
| COPD | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
561 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Ohio
Gary Ansel
Interventional Cardiology · Columbus, OH
John Cheatham
Interventional Cardiology · Columbus, OH
Carlos Sanchez Soto
Interventional Cardiology · Columbus, OH
Steven Yakubov
Interventional Cardiology · Columbus, OH
Timothy Henry
Interventional Cardiology · Cincinnati, OH
Mitchell Silver
Interventional Cardiology · Columbus, OH
Related records
Interventional Cardiology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.